AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also
called NK cells. White blood cells are part of the immune system and NK cells are a type of
white blood cell that are known to kill cancer cells.
This clinical trial is conducted in two phases. The primary objective of Phase 1 is to test
the safety of AB-101 given alone or in combination with rituximab. The primary objective of
Phase 2 is to determine if AB-101 in combination with rituximab has activity in patients with
relapsed/refractory Non-Hodgkin lymphoma of B-cell origin.
Patients will receive eight weekly doses of AB-101 followed by scheduled assessments of
overall health and tumor response.